Time to Akt: Superior tumor-reactive T cells for adoptive immunotherapy

被引：3
|
作者：
van der Waart, Anniek B. [1 ]
Hobo, Willemijn [1 ]
Dolstra, Harry [1 ]
机构：
[1] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Hematol Lab, NL-6525 ED Nijmegen, Netherlands
来源：
ONCOIMMUNOLOGY | 2015年 / 4卷 / 05期
关键词：
adoptive T cell therapy; Akt; dendritic cell; IL-7; IL-15; stem cell transplantation; T-cell differentiation; Wnt; CANCER-THERAPY; GENERATION; INHIBITION;
D O I：
10.1080/2162402X.2014.1003016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
T cells are crucial players in the protection against cancer, and can be used in adoptive cell therapy to prevent or treat relapse. However, their state of differentiation determines their effectiveness, with early memory cells being the most favorable. Here, we discuss restraining of differentiation to engineer the ultimate tumor-reactive T cell.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy
    van der Waart, Anniek B.
    van de Weem, Noortje M. P.
    Maas, Frans
    Kramer, Cynthia S. M.
    Kester, Michel G. D.
    Falkenburg, J. H. Frederik
    Schaap, Nicolaas
    Jansen, Joop H.
    van der Voort, Robbert
    Gattinoni, Luca
    Hobo, Willemijn
    Dolstra, Harry
    BLOOD, 2014, 124 (23) : 3490 - 3500
  • [2] Adoptive immunotherapy with hyper-expanded tumor-reactive T cells
    Plautz, G
    Wang, LX
    Shu, SY
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S24 - S25
  • [3] IDENTIFICATION AND ACTIVATION OF TUMOR-REACTIVE CELLS FOR ADOPTIVE IMMUNOTHERAPY
    TRIOZZI, PL
    STEM CELLS, 1993, 11 (03) : 204 - 211
  • [4] Adoptive immunotherapy of cancer with hyper-expanded tumor-reactive T cells.
    Plautz, GE
    Wang, LX
    BLOOD, 2003, 102 (11) : 407B - 407B
  • [5] Inhibition of Akt-signaling promotes the generation of superior tumor-reactive T cells for immunotherapy post allogeneic stem cell transplantation
    van der Waart, A. B.
    Mousset, C. M.
    Fredrix, H.
    van de Weem, N. M.
    Maas, F.
    Kester, M. G.
    Falkenburg, J. F.
    Schaap, N.
    Jansen, J. H.
    van der Voort, R.
    Gattinoni, L.
    Hobo, W.
    Dolstra, H.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S111 - S112
  • [6] Feasibility and safety of adoptive immunotherapy with ex-vivo generated autologous tumor-reactive T cells in lymphopenic sarcoma patients
    Pedrazzoli, Paolo
    Turin, Maria
    Schiavo, Roberta
    Montini, Enrica
    Secondino, Simona
    Tullio, Cinzia
    Locatelli, Franco
    Maccario, Rita
    Siena, Salvatore
    Montagna, Daniela
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 859 - 859
  • [7] Optimizing Tumor-Reactive γδ T Cells for Antibody-Based Cancer Immunotherapy
    Meraviglia, S.
    Caccamo, N.
    Guggino, G.
    Tolomeo, M.
    Siragusa, S.
    Stassi, G.
    Dieli, F.
    CURRENT MOLECULAR MEDICINE, 2010, 10 (08) : 719 - 726
  • [8] Rapid expansion of tumor-reactive cells from HLA-matched siblings for adoptive immunotherapy of melanoma
    Gottlieb, D. J.
    Micklethwaite, K.
    Bradstock, K. F.
    Li, Y-Ch
    CYTOTHERAPY, 2007, 9 (02) : 133 - 143
  • [9] Cancer-driven exhaustion of tumor-reactive γδ-T cells: Relevance to immunosurveillance and immunotherapy
    Beck, Benjamin H.
    Kim, Hyung-Gyoon
    Haines, Hilary
    Feeley, Kyle
    Lopez, Richard
    CANCER RESEARCH, 2010, 70
  • [10] PROSTATE CANCER IMMUNOTHERAPY USING BI-SPECIFIC TUMOR-REACTIVE T CELLS
    Chan, Robert
    Leen, Ann
    Brenner, Malcolm
    Palapattu, Ganesh
    Vera, Juan
    JOURNAL OF UROLOGY, 2012, 187 (04): : E530 - E530
12345